niacinamide has been researched along with Precursor Cell Lymphoblastic Leukemia-Lymphoma in 7 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Precursor Cell Lymphoblastic Leukemia-Lymphoma: A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In conclusion, sorafenib is active and well tolerated in acute myelogenous leukemia with fms-like tyrosine kinase 3 internal tandem duplication mutation." | 5.15 | Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. ( Andreeff, M; Borthakur, G; Cortes, JE; Faderl, S; Kantarjian, H; Konopleva, M; Mathews, S; Ravandi, F; Verstovsek, S; Wright, JJ; Zhang, W, 2011) |
| "Distinct clinicopathologic acute lymphoblastic leukemia (ALL) entities have been identified, resulting in the adoption of risk-oriented treatment approaches." | 2.44 | [Acute lymphoblastic leukemia with Philadelphia chromosome: treatment with kinase inhibitors]. ( Thomas, X, 2007) |
| "We report the results of a phase I dose escalation trial of the multikinase inhibitor sorafenib in relapsed and refractory acute leukemia patients using an intermittent dosing regimen." | 1.36 | A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias. ( Baker, SD; Carducci, MA; Cho, E; Gore, SD; Karp, JE; Levis, MJ; McDevitt, M; Pratz, KW; Rudek, MA; Smith, BD; Stine, A; Wright, JJ; Zhao, M, 2010) |
| "Sorafenib displays significant antileukemic activity in vitro by inducing cell cycle arrest and apoptosis." | 1.36 | The multikinase inhibitor Sorafenib displays significant antiproliferative effects and induces apoptosis via caspase 3, 7 and PARP in B- and T-lymphoblastic cells. ( Amoroso, F; Boldt, S; Dahlhaus, M; Etro, D; Freund, M; Fuellen, G; Glass, A; Junghanss, C; Lange, S; Neri, LM; Ruck, S; Sawitzky, M; Schult, C; Wolkenhauer, O, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Zerbit, J | 1 |
| Tamburini, J | 1 |
| Goldwirt, L | 1 |
| Decroocq, J | 1 |
| Cayuela, JM | 1 |
| Chapuis, N | 1 |
| Contejean, A | 1 |
| Batista, R | 1 |
| Bouscary, D | 1 |
| Willems, L | 1 |
| Perova, T | 1 |
| Grandal, I | 1 |
| Nutter, LM | 1 |
| Papp, E | 1 |
| Matei, IR | 1 |
| Beyene, J | 1 |
| Kowalski, PE | 1 |
| Hitzler, JK | 1 |
| Minden, MD | 1 |
| Guidos, CJ | 1 |
| Danska, JS | 1 |
| Kurosu, T | 1 |
| Ohki, M | 1 |
| Wu, N | 1 |
| Kagechika, H | 1 |
| Miura, O | 1 |
| Pratz, KW | 1 |
| Cho, E | 1 |
| Levis, MJ | 1 |
| Karp, JE | 1 |
| Gore, SD | 1 |
| McDevitt, M | 1 |
| Stine, A | 1 |
| Zhao, M | 1 |
| Baker, SD | 1 |
| Carducci, MA | 1 |
| Wright, JJ | 2 |
| Rudek, MA | 1 |
| Smith, BD | 1 |
| Schult, C | 1 |
| Dahlhaus, M | 1 |
| Ruck, S | 1 |
| Sawitzky, M | 1 |
| Amoroso, F | 1 |
| Lange, S | 1 |
| Etro, D | 1 |
| Glass, A | 1 |
| Fuellen, G | 1 |
| Boldt, S | 1 |
| Wolkenhauer, O | 1 |
| Neri, LM | 1 |
| Freund, M | 1 |
| Junghanss, C | 1 |
| Borthakur, G | 1 |
| Kantarjian, H | 1 |
| Ravandi, F | 1 |
| Zhang, W | 1 |
| Konopleva, M | 1 |
| Faderl, S | 1 |
| Verstovsek, S | 1 |
| Mathews, S | 1 |
| Andreeff, M | 1 |
| Cortes, JE | 1 |
| Thomas, X | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Study of BAY 43-9006 (NSC 724772) in Patients With Acute Leukemias, Myelodysplastic Syndromes and Chronic Myeloid Leukemia in Blast Phase[NCT00217646] | Phase 1 | 36 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for niacinamide and Precursor Cell Lymphoblastic Leukemia-Lymphoma
| Article | Year |
|---|---|
[Acute lymphoblastic leukemia with Philadelphia chromosome: treatment with kinase inhibitors].
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Benzamides; Benzenesulfonates; Dasatinib; Drug R | 2007 |
1 trial available for niacinamide and Precursor Cell Lymphoblastic Leukemia-Lymphoma
| Article | Year |
|---|---|
Phase I study of sorafenib in patients with refractory or relapsed acute leukemias.
Topics: Adult; Aged; Aged, 80 and over; Benzenesulfonates; Female; Humans; Leukemia, Lymphocytic, Chronic, B | 2011 |
5 other studies available for niacinamide and Precursor Cell Lymphoblastic Leukemia-Lymphoma
| Article | Year |
|---|---|
Asciminib and ponatinib combination in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Fusion Proteins, bcr-abl; Humans; Imidazoles; Niacinamide; Philadelphia Chromosome; Precursor Cell L | 2021 |
Therapeutic potential of spleen tyrosine kinase inhibition for treating high-risk precursor B cell acute lymphoblastic leukemia.
Topics: Administration, Oral; Adult; Aminopyridines; Animals; Cell Proliferation; Cell Survival; Child; Fema | 2014 |
Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
Topics: Acetophenones; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Benzenesulfona | 2009 |
A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Extracellular Signal-Regul | 2010 |
The multikinase inhibitor Sorafenib displays significant antiproliferative effects and induces apoptosis via caspase 3, 7 and PARP in B- and T-lymphoblastic cells.
Topics: Antineoplastic Agents; Apoptosis; B-Lymphocytes; Benzenesulfonates; Caspase 3; Caspase 7; Cell Line, | 2010 |